With a new month upon us, now could be a good time to consider making some new additions to your portfolio.
Listed below are three high quality ASX shares that could be great options for April. Here's what you need to know about them:
Image source: Getty Images
Adore Beauty Group Limited (ASX: ABY)
Adore Beauty is a beauty-focused ecommerce company that has been growing very strongly in FY 2021. Last month the company released its half year results and revealed an 85% increase in revenue to $96.2 million and a 188% jump in operating earnings to $5.2 million. Positively, this is still well short of its overall market opportunity. And thanks to the shift online and the low penetration of beauty sales online compared to other Western markets, Adore Beauty looks well-placed for growth over the long term.
UBS is positive on the company. It recently put a buy rating and $6.20 price target on its shares.
CSL Limited (ASX: CSL)
Another ASX share to consider is CSL. This biotechnology's CSL Behring business has a portfolio filled with lucrative life-saving plasma therapies. Whereas its Seqirus business has a range of important influenza vaccines and anti-venom products. Between the two businesses, CSL is generating billions of dollars of sales each year and reinvesting ~11% of this back into its research and development activities. This has resulted in the company having a number of exciting products under development with the potential to underpin solid long term earnings growth.
Citi recently upgraded CSL's shares to a buy rating with a $310 price target.
REA Group Limited (ASX: REA)
A final ASX share to consider buying is REA Group. It is of course the dominant player in real estate listings in the Australian market with its realestate.com.au website. In addition to this, the company has a collection of complementary businesses in the local market and a number of international brands. REA Group looks well-placed for growth in the coming years thanks to the improving housing market, new revenue streams, cost cutting, and price increases.
Morgan Stanley is positive on the company's prospects. It has an overweight rating and $175.00 price target on its shares.
